A division of the Amedart Group of Companies is organizing drug production in Tomsk for 2 billion rubles.

The project will be implemented in two phases. During the first phase, a production facility for active pharmaceutical ingredients will be built on a 2.24-hectare site in the Tomsk Special Economic Zone. The second phase will include the construction of a plant for the production of finished dosage forms—tablets, injections, and other forms of medications used in oncology and antiviral therapy.

The project will employ approximately 250 qualified specialists. Training will be provided by the Siberian State Medical University, with which the investor has already signed a cooperation agreement. Plans include developing specialized educational programs and organizing internships for students and young scientists.

According to regional authorities, when selecting the site, the company considered the Tomsk Region's high scientific and technical potential, the developed research base of its universities and academic institutes, and the readiness of the SEZ infrastructure. The launch of the facility is expected to stimulate the development of a pharmaceutical cluster in the region, uniting research centers, manufacturing companies, and technology startups.

According to SPARK-Interfax, Amekhim LLC was registered on July 18, 2025, in Tomsk. Its CEO is Andrey Kolokoltsov. The legal entity is part of the Amedart Group of Companies (Moscow), one of Russia's largest developers and manufacturers of original and generic medications for the treatment of oncological, endocrine, and viral diseases. The group's parent company, Amedart LLC, was registered on December 4, 2009. Its beneficiary is Alexey Ignatyev, and its CEO is Andrey Kolokoltsov. As of the end of 2024, the LLC's net profit amounted to 1.22 billion rubles.

The group's facilities have established production of a number of vital medications used in the treatment of cancer, diabetes, and HIV. The Tomsk project is expected to allow Amedart Group to expand its production capacity and broaden its product range.

The group of companies operates a production complex in the Technopolis Moscow Special Economic Zone (SEZ), comprising seven sites. A 600 million ruble production facility was launched at one of these sites in 2022. It manufactures medications from the VED list for the treatment of cancer, diabetes, and HIV, as well as antibiotics and immunosuppressants. The site also produces sterile and non-sterile solid and liquid dosage forms, as well as biotechnological drugs. The complex is equipped with analytical and microbiological laboratories and operates in accordance with GMP requirements.

The development of the Amehim project in Tomsk is taking place against the backdrop of expanding production programs at leading Russian pharmaceutical companies. In St. Petersburg, for example, Baltpharma, a resident of the Special Economic Zone (SEZ), part of the R-Pharm Group, is implementing an investment project worth over 2.5 billion rubles to build a new 5,500 square meter facility in the Novoorlovskaya cluster. The project is aimed at fulfilling the terms of an offset contract with the city signed in 2023, which provides for the creation of a high-tech, full-cycle production facility and the creation of approximately 300 jobs.

Another major pharmaceutical project is underway in the Moscow region: the PharmEco group of companies, together with Sberbank and the regional Ministry of Investment, Industry, and Science, are establishing a cancer drug production facility in Chernogolovka. The investment will total 9.1 billion rubles, part of which will be financed by Sberbank. A 30,000-square-meter plot of land has already been allocated for the project, and the plant itself will cover over 10,000 square meters. By 2029, the company plans to begin full-cycle production of 18 medications, create 150 jobs, and achieve annual revenues of 8-10 billion rubles.